TN2009000004A1 - Compositions and methods for the treatment of mucormycosis and other fungal diseases - Google Patents

Compositions and methods for the treatment of mucormycosis and other fungal diseases

Info

Publication number
TN2009000004A1
TN2009000004A1 TN2009000004A TN2009000004A TN2009000004A1 TN 2009000004 A1 TN2009000004 A1 TN 2009000004A1 TN 2009000004 A TN2009000004 A TN 2009000004A TN 2009000004 A TN2009000004 A TN 2009000004A TN 2009000004 A1 TN2009000004 A1 TN 2009000004A1
Authority
TN
Tunisia
Prior art keywords
antifungal agent
iron chelating
fungal condition
chelating compound
fungal
Prior art date
Application number
TN2009000004A
Other languages
English (en)
French (fr)
Inventor
Brad J Spellberg
John E Edwards
Ashraf S Ibrahim
Original Assignee
Los Angeles Biomed Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Biomed Res Inst filed Critical Los Angeles Biomed Res Inst
Publication of TN2009000004A1 publication Critical patent/TN2009000004A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TN2009000004A 2006-07-13 2009-01-12 Compositions and methods for the treatment of mucormycosis and other fungal diseases TN2009000004A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83109906P 2006-07-13 2006-07-13
US89762007P 2007-01-26 2007-01-26
US90407507P 2007-02-27 2007-02-27
PCT/US2007/016065 WO2008008537A2 (en) 2006-07-13 2007-07-13 Combi) compositions for the treatment of mucormycosis. comprising iron chelator and antifungal agent

Publications (1)

Publication Number Publication Date
TN2009000004A1 true TN2009000004A1 (en) 2010-08-19

Family

ID=38610625

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2009000004A TN2009000004A1 (en) 2006-07-13 2009-01-12 Compositions and methods for the treatment of mucormycosis and other fungal diseases

Country Status (18)

Country Link
US (1) US20100129434A1 (enExample)
EP (2) EP2043636A2 (enExample)
JP (2) JP2009543788A (enExample)
KR (1) KR20090036587A (enExample)
AU (1) AU2007272781B2 (enExample)
BR (1) BRPI0714221A2 (enExample)
CA (1) CA2657634A1 (enExample)
CL (1) CL2007002026A1 (enExample)
IL (1) IL196389A0 (enExample)
MA (1) MA30625B1 (enExample)
MX (1) MX2009000506A (enExample)
NO (1) NO20090565L (enExample)
NZ (1) NZ574862A (enExample)
RU (1) RU2464024C2 (enExample)
SG (1) SG177122A1 (enExample)
TN (1) TN2009000004A1 (enExample)
TW (1) TWI448285B (enExample)
WO (1) WO2008008537A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2755273A1 (en) * 2009-03-19 2010-09-23 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
US8980876B2 (en) 2010-10-28 2015-03-17 The Procter & Gamble Company Inhibition of microbial growth by aconitase inhibition
US20150246027A1 (en) * 2012-11-12 2015-09-03 Cipla Limited Fixed dose pharmaceutical composition comprising deferasirox and deferiprone
US11229685B2 (en) 2013-01-29 2022-01-25 Case Western Reserve University Fungal iron acquisition inhibitors and uses thereof
US20160199361A1 (en) * 2013-08-19 2016-07-14 Rutgers, The State University Of New Jersey Method of Inducing An Anti-Retroviral Immune Response By Counter-Acting Retro-Virus Induced Anti-Apoptosis
WO2016025611A2 (en) * 2014-08-13 2016-02-18 Zoneone Pharma, Inc. Pharmaceutical formulations of chelating agents as a metal removal treatment system
WO2016025559A1 (en) * 2014-08-13 2016-02-18 Zoneone Pharma, Inc. Pharmaceutical formulations of and methods to prepare chelating agents for efficient metal removal treatment systems
US11298364B2 (en) * 2015-08-31 2022-04-12 The University Of Adelaide Methods and products for preventing and/or treating microorganism infections comprising iron chelators and non-iron porphyrins
US10960002B2 (en) 2016-05-13 2021-03-30 The Brigham And Women's Hospital, Inc. Volatile metabolite profiles for the diagnosis and treatment of Mucorales fungi
FR3095755A1 (fr) * 2019-05-10 2020-11-13 Balmes Transplantation Nouveaux médicaments cytoprotecteurs
CN113905715B (zh) 2019-06-28 2025-04-15 宝洁公司 光增强处理方法
JP2023057423A (ja) * 2021-10-11 2023-04-21 国立大学法人 熊本大学 ムコール症治療薬

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8329043D0 (en) * 1983-10-31 1983-11-30 Hider R C Pharmaceutical compositions
US4698431A (en) * 1985-11-12 1987-10-06 The United States Of America As Represented By The United States Department Of Energy Hydroxypyridonate chelating agents
PH31594A (en) * 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
WO1999009997A1 (en) * 1997-08-26 1999-03-04 Board Of Regents, The University Of Texas System Edta and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
DE50111949D1 (de) * 2000-12-16 2007-03-15 Alstom Technology Ltd Komponente einer Strömungsmaschine
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
ITMI20022447A1 (it) * 2002-11-19 2004-05-20 Carlo Ghisalberti Uso di piridinoni nel trattamento della purpura capillare ed affezioni cutanee correlate.
AU2003302274A1 (en) * 2002-12-31 2004-07-29 Novartis Ag Aerosolizable pharmaceutical formulation for fungal infection therapy
WO2004108114A2 (en) * 2003-03-31 2004-12-16 Dinesh Shantilal Patel Anti-fungal composition and a process for its manufacture
DE10356409B4 (de) * 2003-11-28 2006-12-28 Biofrontera Discovery Gmbh Neues Arzneimittel Oxachelin und Derivate

Also Published As

Publication number Publication date
AU2007272781A1 (en) 2008-01-17
TW200816994A (en) 2008-04-16
MX2009000506A (es) 2009-05-20
BRPI0714221A2 (pt) 2013-01-01
WO2008008537A2 (en) 2008-01-17
MA30625B1 (fr) 2009-08-03
JP2009543788A (ja) 2009-12-10
KR20090036587A (ko) 2009-04-14
EP2043636A2 (en) 2009-04-08
CA2657634A1 (en) 2008-01-17
TWI448285B (zh) 2014-08-11
IL196389A0 (en) 2009-09-22
AU2007272781B2 (en) 2012-10-18
RU2464024C2 (ru) 2012-10-20
NO20090565L (no) 2009-03-30
JP2013040212A (ja) 2013-02-28
EP2412371A1 (en) 2012-02-01
US20100129434A1 (en) 2010-05-27
SG177122A1 (en) 2012-01-30
WO2008008537A3 (en) 2008-04-24
CL2007002026A1 (es) 2008-06-06
NZ574862A (en) 2012-02-24
RU2009104961A (ru) 2010-08-20

Similar Documents

Publication Publication Date Title
TN2009000004A1 (en) Compositions and methods for the treatment of mucormycosis and other fungal diseases
NZ597489A (en) Methods for treating conditions associated with MASP-2 dependent complement activation
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2008050329A3 (en) Novel sirnas and methods of use thereof
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
WO2007128526A3 (en) Combination comprising a vegf inhibitor and a serine protease for treating neovascular diseases
WO2007112000A3 (en) Treatment of pain
GB2487166A (en) Novel parasite therapy
MX2010007584A (es) Inhibidores de proteina cinasa y uso de los mismos.
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
MY150682A (en) Method for using vasopressin antagonist with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
MX2009005649A (es) Tratamiento para mieloma multiple.
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
MX2022009197A (es) Metodos de tratamiento para deficiencia de alfa-1 antitripsina.
TW200639159A (en) Treatment of pain
WO2008077062A3 (en) Suppression of stat3 reactivation after src kinase inhibition to treat cancer
WO2007030360A3 (en) P13k inhibitors for the treatment of endometriosis
TW200742580A (en) Methods for treating nephrolithiasis
WO2007015841A3 (en) A method for treating preeclampsia
WO2002055022A3 (en) Active metabolite of antifungal compound
NO20035038D0 (no) Forhindring av avhengighet ved smertebehandling
WO2008016665A3 (en) Imidazoacridine compounds for treating flt3 -mediated disorders
WO2006101909A3 (en) Combination therapy for treating or preventing diseases
TNSN08479A1 (en) Method of treatment of hereditary hemochromatosis